AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 142 min read$PDSB

PDS Biotechnology Corp (PDSB): Termination of a Material Definitive Agreement

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Exhibit 99.1 PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks Pr

Original reporting
SEC EDGAR 8-K
Published Sep 14, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$PDSB
Bullish
high confidence
Mentioned
$PDSB
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PDSBBullishMed
01

Why it matters

The financing strengthens the balance sheet and signals confidence from a high‑profile investor, potentially supporting the stock price in the near term.

02

Market read

New capital raise and board appointment provide fresh catalyst for a micro‑cap biotech, with potential short‑term price support.

03

What to watch

Milestone closing contingent on Phase 3 filing; future financing depends on regulatory approval.

Relevance 6/10Novelty 8/10Timing: filed Sep 14 2026 (same‑day filing)

Background

PDS Biotechnology (Nasdaq: PDSB) announced a private placement raising $11.3 M and added Dr. Patrick Soon‑Shiong to its board, alongside a licensing option for its HPV immunotherapy.

Company-level read

Ticker impact

$PDSBBullishHigh confidence
Context

SEC 8‑K reports initial closing of a $11.3 M PIPE financing and appointment of Dr. Patrick Soon‑Shiong to the board.

Expected impact

Modest upside potential as cash infusion reduces dilution concerns and adds credibility with high‑profile board member.

Evidence & confidence

New financing of $11.3 M is material for a micro‑cap biotech; the involvement of a renowned oncologist may attract investor interest.

Market effects

Sector

Adds funding to the oncology immunotherapy sector, potentially boosting peer sentiment.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minor global impact; highlights continued interest in cancer vaccine platforms.

Counterpoint

What could challenge this read

The PIPE dilution and modest size may not be enough to change the company's long‑term risk profile.

Key entities

  • company
    PDS Biotechnology Corp

    Clinical‑stage biotech developing immunotherapies.

  • individual
    Patrick Soon‑Shiong

    Renowned physician‑scientist and board member.

  • investor
    Nant Capital

    Lead investor in the PIPE transaction.

Read at source← All news

Related articles

OCT 21
$PDSBMedAI 8/10

PDS Biotechnology updates corporate presentation highlighting PDS0301 Phase 2 results, near-term data readouts

PDS Biotechnology updated its corporate presentation, reporting strong interim results for PDS0301 in combination with chemotherapy, including a 71.4% objective response rate and median OS exceeding 34 months in a Phase 2 mCRC trial. The company also highlighted upcoming data readouts and a planned Phase 3 protocol for PDS0301, as well as results for PDS0101 in a Phase 2 trial. PDS0101 is seeking partnerships for further development.

tradingview.com1 min
OCT 16
$PDSBMed

PDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal Cancer

PDS Biotechnology (NASDAQ: PDSB) is planning a Phase III trial for PDS0301 in metastatic colorectal cancer. Early studies showed promising results, with a 70% response rate at six months. The company has discussed the trial design with the FDA and aims to start the trial in early 2027. PDS0301 is being evaluated in combination with hepatic artery infusion pump therapy, which showed durable responses and manageable side effects.

finance.yahoo.com2 min
OCT 13
$PDSBMedAI 8/10

PDSB Jumps As JAMA Data And Nant Capital Deal Reshape The Story

PDS Biotechnology (PDSB) shares rose 13.08% on October 13, 2026, driven by positive clinical data and a financing deal. The company reported a 36% objective response rate in a Phase 2 trial published in JAMA Oncology, outperforming historical benchmarks. PDSB also secured $11.3M in funding from Nant Capital, though at a dilutive price. The stock's recent surge reflects optimism around its immunotherapy pipeline and strategic partnerships, despite its fragile financials.

stockstotrade.com6 min
SEP 22
$PDSBMedAI 8/10

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic…

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology 39.3 months median overall survival in first-line (1L) R/M immune

SEC EDGAR 8-K2 min
SEP 8
$BJDXMedAI 8/10

5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

rttnews.com3 min